What is ACIU's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.25B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ACIU?

P/E (TTM) is n/a and 52-week range is CHF2.10 to CHF4.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ACIU figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ACIU?

The company profile lists revenue (TTM) near $17M, net income (TTM) near -$4.17B, EPS (TTM) near -CHF0.43 when available from the market-data feed. Figures are informational and may lag live markets.

Where is AC Immune SA based, and what identifiers does Chartloom list?

The company context section lists headquarters in Lausanne, Vaud, CH, 101.8M shares outstanding, ISIN CH0329023102 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

AC Immune SA

$ACIU

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Employees

122

Website

www.acimmune.com/

IPO

2016-09-23

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)